Form D · Biotechnology
Kaigene, Inc.
Rockville, MD · CIK 0001919055
Offering snapshot reported Oct 14, 2026 · SEC filing
- Reported sold
- $55M Offering amount: $73.4M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 14, 2026 | Initial | $54,958,229 | No comparison | 22 | SEC filing |
| Mar 29, 2022 | Initial | $1,350,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601199
Source: Form D, filed Oct 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tae Heum Jeong | Director |
| Kyunghyun Min | Director |
| Jihoon Park | Executive |
| Minjae Shin | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9800 Medical Center Drive A110
Rockville, MD, 20850
Phone: 301-655-8569
Rockville, MD, 20850
Phone: 301-655-8569